Aktieanalys

Vitrolife: The company enters 2023 with good progress - Redeye

Redeye Publicerad: 21 Apr 2023 10:44

Vitrolife’s enters 2023 with good progress. The organic growth is 9%, with support from all three lines of business. It is also reassuring that Genetic Services delivers a quarter with 7% organic growth. The gross margin is an important value driver, and the 56.7% gross margin is also a decisive outcome. The overall result is ahead of both our and the market expectations, and we expect a distinctive 5%+ positive share price reaction on the back of Vitrolife’s Q1. Our base case valuation ahead of Q1 was SEK285 and a Bull Case of SEK400 and a Bear Case of SEK140.

Länk till analysen i sin helhet: https://www.redeye.se/research/895988/vitrolife-the-company-enters-2023-with-good-progress?utm_source=finwire&utm_medium=RSS

Nyheter om Vitrolife

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!